Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5053f82a7cd17c60822674b657cfb89e |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 |
filingDate |
2017-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32ad655c1c4699081708494ba10385c1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf96b8689c0ad96b4c30b8b087e2c85c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_816da4fc028508788807ad7a1751588c |
publicationDate |
2018-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2018092895-A1 |
titleOfInvention |
Method of treatment of hepatitis c |
abstract |
The present invention relates to pharmaceutical composition of calcium channel blocker for the method of treatment of hepatitis C in humans. The methods of the present invention can be used in patients with hepatitis C administering calcium channel blocker such as Isradipine, optionally in combination with one or more anti-hepatitis C drugs. |
priorityDate |
2016-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |